Clinical trial
Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity
NCT00219700 is registered in ClinicalTrials.gov with PLx Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity
- Lead sponsor
- PLx Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- November 30, 2005
- Enrollment
- 125
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.